Outlook Therapeutics

Outlook Therapeutics

  • Founded: 2011
  • Location: Cranbury, NJ
  • Employee range: 1-50
  • Funding: 100-500M



job board

Short description:

Contact us to add description: recruit@workinbiotech.com

Drug notes:

Contact us to add description: recruit@workinbiotech.com

Long description:

Outlook Therapeutics is developing antibody-based therapeutics for ophthalmic disorders. Wet age-related macular degeneration (Wet AMD) is the leading cause of vision loss among people over age 50 and is triggered by abnormal blood vessel growth. Bevacizumab-vikg is a recombinant humanized monoclonal antibody that antagonizes the activity of the protein VEGF, a protein that regulates blood vessel formation. Outlook is developing the first ophthalmic formulation of bevacizumab that can be delivered to patients via intravitreal injection. Following injection and VEGF inhibition, vascular leakage can be reduced with the potential of deploying the therapy for patients with wet AMD.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com